Business Description
TNF Pharmaceuticals Inc
NAICS : 541713
SIC : 2833
ISIN : US62856X1028
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 502.54 | |||||
Equity-to-Asset | 0.01 | |||||
Debt-to-Equity | 0.07 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -16.6 | |||||
3-Year EPS without NRI Growth Rate | -19.4 | |||||
3-Year FCF Growth Rate | -30.7 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
14-Day RSI | 31.55 | |||||
12-1 Month Momentum % | -88.55 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.48 | |||||
Quick Ratio | 2.48 | |||||
Cash Ratio | 2.26 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.7 | |||||
Shareholder Yield % | 2.02 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -176 | |||||
ROA % | -83.58 | |||||
ROIC % | -103.32 | |||||
3-Year ROIIC % | -67.48 | |||||
ROC (Joel Greenblatt) % | -21820.85 | |||||
ROCE % | -80.77 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | 0.7 | |||||
EV-to-EBITDA | 0.7 | |||||
EV-to-FCF | 0.88 | |||||
Earnings Yield (Greenblatt) % | 142.62 | |||||
FCF Yield % | -284.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
TNF Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -9.947 | ||
Beta | 2.01 | ||
Volatility % | 68.71 | ||
14-Day RSI | 31.55 | ||
14-Day ATR (€) | 0.000007 | ||
20-Day SMA (€) | 1.89 | ||
12-1 Month Momentum % | -88.55 | ||
52-Week Range (€) | 1.89 - 16.35 | ||
Shares Outstanding (Mil) | 2.37 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
TNF Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
TNF Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
TNF Pharmaceuticals Inc Frequently Asked Questions
What is TNF Pharmaceuticals Inc(FRA:DQS0)'s stock price today?
When is next earnings date of TNF Pharmaceuticals Inc(FRA:DQS0)?
Does TNF Pharmaceuticals Inc(FRA:DQS0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |